top of page

Olivier Negre


Olivier NEGRE, PhD

Olivier developed his expertise in preclinical research and translational science through more than 20 years of experience in biotherapies. After working on recombinant vaccines with Bioprotein Technologies, he joined Genetix France to develop gene therapies for beta-thalassemia and sickle cell disease. He led the French Research & Development team for nine years and was in charge of specialized bioassays for gene therapy clinical trials. He transitioned to bluebird bio Cambridge MA (USA) as Director Preclinical & Translational Research and was the head of the Stem Cell Group for five years. Overall, he contributed to the development of the first approved gene therapy for beta-thalassemia (Zynteglo), from preclinical studies to marketing authorization. In 2019, Olivier participated in founding Biotherapy Partners to foster drug developments in the field of cell and gene therapies. Olivier graduated from ENSTBB engineering school in Bordeaux and earned a doctorate degree in cell and molecular biology from Paris Diderot University. He is currently Chief Scientific Officer at Smart Immune, Partner at Biotherapy Partners, board member of the French Society of Cell and Gene Therapy (SFTCG), Co-President of the think tank Gene and Cell Therapy Institute (G&CTI) in Paris, and member of the EuroGCT consortium,

T2EVOLVE Logo.png
bottom of page